Ribociclib (RIBO) 1 letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR1), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial

Authors
Category Primary study
JournalAnnals of Oncology
Year 2018
This article has no abstract
Epistemonikos ID: 40c00d474088b31e68be787c0a66a2e5312cf43f
First added on: Feb 11, 2025